Publication:
The International Criteria for Behçet's Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria

dc.contributor.authorF. Davatchien_US
dc.contributor.authorS. Assaad-Khalilen_US
dc.contributor.authorK. T. Calamiaen_US
dc.contributor.authorJ. E. Crooken_US
dc.contributor.authorB. Sadeghi-Abdollahien_US
dc.contributor.authorM. Schirmeren_US
dc.contributor.authorT. Tzellosen_US
dc.contributor.authorC. C. Zouboulisen_US
dc.contributor.authorM. Akhlagien_US
dc.contributor.authorA. Al-Dalaanen_US
dc.contributor.authorZ. S. Alekberovaen_US
dc.contributor.authorA. A. Alien_US
dc.contributor.authorA. Altenburgen_US
dc.contributor.authorE. Arromdeeen_US
dc.contributor.authorM. Baltacien_US
dc.contributor.authorM. Bastosen_US
dc.contributor.authorS. Benamouren_US
dc.contributor.authorI. Ben Ghorbelen_US
dc.contributor.authorA. Boyvaten_US
dc.contributor.authorL. Carvalhoen_US
dc.contributor.authorW. Chenen_US
dc.contributor.authorE. Ben-Chetriten_US
dc.contributor.authorC. Chams-Davatchien_US
dc.contributor.authorJ. A. Correiaen_US
dc.contributor.authorJ. Crespoen_US
dc.contributor.authorC. Diasen_US
dc.contributor.authorY. Dongen_US
dc.contributor.authorF. Paixão-Duarteen_US
dc.contributor.authorK. Elmuntaseren_US
dc.contributor.authorA. V. Elonakoven_US
dc.contributor.authorJ. Graña Gilen_US
dc.contributor.authorA. A. Haghdoosten_US
dc.contributor.authorR. M. Hayanien_US
dc.contributor.authorH. Houmanen_US
dc.contributor.authorA. R. Isayevaen_US
dc.contributor.authorA. R. Jamshidien_US
dc.contributor.authorP. Kaklamanisen_US
dc.contributor.authorA. Kumaren_US
dc.contributor.authorA. Kyrgidisen_US
dc.contributor.authorW. Madanaten_US
dc.contributor.authorA. Nadjien_US
dc.contributor.authorK. Nambaen_US
dc.contributor.authorS. Ohnoen_US
dc.contributor.authorI. Olivierien_US
dc.contributor.authorJ. Vaz Pattoen_US
dc.contributor.authorN. Pipitoneen_US
dc.contributor.authorM. V. De Queirozen_US
dc.contributor.authorF. Ramosen_US
dc.contributor.authorC. Resendeen_US
dc.contributor.authorC. M. Rosaen_US
dc.contributor.authorC. Salvaranien_US
dc.contributor.authorM. J. Serraen_US
dc.contributor.authorF. Shahramen_US
dc.contributor.authorH. Shamsen_US
dc.contributor.authorK. E. Sharquieen_US
dc.contributor.authorM. Sliti-Khanfiren_US
dc.contributor.authorT. Tribolet De Abreuen_US
dc.contributor.authorC. Vasconcelosen_US
dc.contributor.authorJ. Vedesen_US
dc.contributor.authorB. Wechsleren_US
dc.contributor.authorY. K. Chengen_US
dc.contributor.authorZ. Zhangen_US
dc.contributor.authorN. Ziaeien_US
dc.contributor.otherTehran University of Medical Sciencesen_US
dc.contributor.otherAlexandria Medical Schoolen_US
dc.contributor.otherMayo Clinic in Jacksonville, Floridaen_US
dc.contributor.otherMedizinische Universitat Innsbrucken_US
dc.contributor.otherStadtisches Klinikum Dessauen_US
dc.contributor.otherGerman Registry of Adamantiades-Behçet's Diseaseen_US
dc.contributor.otherKing Saud Universityen_US
dc.contributor.otherV.A. Nasonova Research Institute of Rheumatologyen_US
dc.contributor.otherThe Aga Khan University Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHospital São Teotónioen_US
dc.contributor.otherCentre Hospitalier Universitaire Ibn-Rochden_US
dc.contributor.otherDepartment of Internal Medicineen_US
dc.contributor.otherAnkara Universitesien_US
dc.contributor.otherHospital Geral de Santo Antonioen_US
dc.contributor.otherChang Gung Universityen_US
dc.contributor.otherHadassah University Medical Centreen_US
dc.contributor.otherCentro Hospitalar e Universitario de Coimbraen_US
dc.contributor.otherSao Joao Hospitalen_US
dc.contributor.otherPeking Union Medical Collegeen_US
dc.contributor.otherFernando da Fonseca Hospitalen_US
dc.contributor.otherKadisia Clinicen_US
dc.contributor.otherComplejo Hospitalario Universitario Juan Canalejoen_US
dc.contributor.otherUniversity of Baghdaden_US
dc.contributor.otherAzerbaycan Tibb Universitetien_US
dc.contributor.otherMedical Centeren_US
dc.contributor.otherAll India Institute of Medical Sciences, New Delhien_US
dc.contributor.otherJordan Hospitalen_US
dc.contributor.otherHokkaido University School of Medicineen_US
dc.contributor.otherPotenza and Madonna Delle Grazie Hospitalen_US
dc.contributor.otherInstituto Portugues de Reumatologiaen_US
dc.contributor.otherAzienda Ospedaliera Santa Maria Nuova di Reggio Emiliaen_US
dc.contributor.otherSanta Maria Hospital, Lisbonen_US
dc.contributor.otherUniversity of Lisbon Faculty of Medicine, Institute of Molecular Medicineen_US
dc.contributor.otherSanto António dos Capuchos Hospitalen_US
dc.contributor.otherHospital do Espirito Santoen_US
dc.contributor.otherHospital Sousa Martinsen_US
dc.contributor.otherHopital Universitaire Pitie Salpetriereen_US
dc.contributor.otherGleneagles Hospitalen_US
dc.contributor.otherPeking Universityen_US
dc.date.accessioned2018-11-09T02:39:48Z
dc.date.available2018-11-09T02:39:48Z
dc.date.issued2014-03-01en_US
dc.description.abstractObjective Behçet's disease (BD) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test. Low sensitivity of the currently applied International Study Group (ISG) clinical diagnostic criteria led to their reassessment. Methods An International Team for the Revision of the International Criteria for BD (from 27 countries) submitted data from 2556 clinically diagnosed BD patients and 1163 controls with BD-mimicking diseases or presenting at least one major BD sign. These were randomly divided into training and validation sets. Logistic regression, 'leave-one-country-out' cross-validation and clinical judgement were employed to develop new International Criteria for BD (ICBD) with the training data. Existing and new criteria were tested for their performance in the validation set. Results For the ICBD, ocular lesions, oral aphthosis and genital aphthosis are each assigned 2 points, while skin lesions, central nervous system involvement and vascular manifestations 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD. In the training set, 93.9% sensitivity and 92.1% specificity were assessed compared with 81.2% sensitivity and 95.9% specificity for the ISG criteria. In the validation set, ICBD demonstrated an unbiased estimate of sensitivity of 94.8% (95% CI: 93.4-95.9%), considerably higher than that of the ISG criteria (85.0%). Specificity (90.5%, 95% CI: 87.9-92.8%) was lower than that of the ISG-criteria (96.0%), yet still reasonably high. For countries with at least 90%-of-cases and controls having a pathergy test, adding 1 point for pathergy test increased the estimate of sensitivity from 95.5% to 98.5%, while barely reducing specificity from 92.1% to 91.6%. Conclusion The new proposed criteria derived from multinational data exhibits much improved sensitivity over the ISG criteria while maintaining reasonable specificity. It is proposed that the ICBD criteria to be adopted both as a guide for diagnosis and classification of BD. © 2013 European Academy of Dermatology and Venereology.en_US
dc.identifier.citationJournal of the European Academy of Dermatology and Venereology. Vol.28, No.3 (2014), 338-347en_US
dc.identifier.doi10.1111/jdv.12107en_US
dc.identifier.issn14683083en_US
dc.identifier.issn09269959en_US
dc.identifier.other2-s2.0-84894462149en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/34287
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84894462149&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleThe International Criteria for Behçet's Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteriaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84894462149&origin=inwarden_US

Files

Collections